In vivo evaluation of poly-l-asparagine nanocapsules as carriers for anti-cancer drug delivery

DocumentFichier
Fichier pdf chargé le 08/01/2015 à 10:17:12

(version éditeur)
fichier
TitreIn vivo evaluation of poly-l-asparagine nanocapsules as carriers for anti-cancer drug delivery
Type de publicationArticle de revue
AuteurRivera-Rodriguez, Gustavo R, Lollo, Giovanna , Montier, Tristan, Benoît, Jean-Pierre , Passirani-Malleret, Catherine, Alonso, Maria José, Torres, Dolores
EditeurElsevier
TypeArticle scientifique dans une revue à comité de lecture
Année2013
LangueAnglais
Date2013 Dec 15
Numéro1
Pagination83-9
Volume458
Titre de la revueInternational Journal of Pharmaceutics
ISSN1873-3476
Mots-clésAnimals, Antineoplastic Agents, Asparagine, Cell Line, Tumor, Chemistry, Pharmaceutical, Drug Carriers, Drug Delivery Systems, Glioma, Mice, Nanocapsules, Particle Size, Taxoids, Tissue Distribution
Résumé en anglais

Here, we report the in vivo proof of-concept of a novel nanocarrier, poly-l-asparagine (PASN) nanocapsules, as an anticancer targeted drug delivery system. The nanocapsules were loaded with the fluorescent marker DiD (1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine perchlorate) and also with the model drug docetaxel to evaluate the biodistribution and efficacy profiles in healthy and glioma-bearing mice, respectively. Regardless of their cargo, the nanocapsules presented a size close to 180 nm, a surface charge around -40 mV and an encapsulation efficiency of 75-90%. The biodistribution study in healthy mice showed that PASN nanocapsules led to a two- and three-fold increment in the mean residence time (MRT) and area under the curve (AUC) values, respectively, compared to those of a non-polymeric nanoemulsion. Finally, the efficacy/toxicity study indicated that the encapsulated drug was as efficacious as the commercial formulation (Taxotere(®)), with the additional advantage of being considerably less toxic. Overall, these results suggest the potential of PASN nanocapsules as drug nanocarriers in anticancer therapy.

URL de la noticehttp://okina.univ-angers.fr/publications/ua6672
DOI10.1016/j.ijpharm.2013.09.038
Lien vers le document

http://dx.doi.org/10.1016/j.ijpharm.2013.09.038

Autre titreInt J Pharm
Identifiant (ID) PubMed24140546